Document is current
Any future updates will be listed below
-
Authors
Li, Yi-Nan https://orcid.org/0000-0001-8934-9361
Chen, Chih-Wei
Trinh-Minh, Thuong
Zhu, Honglin
Matei, Alexandru-Emil
Györfi, Andrea-Hermina
Kuwert, Frederic
Hubel, Philipp
Ding, Xiao
Manh, Cuong Tran
Xu, Xiaohan
Liebel, Christoph
Fedorchenko, Vladyslav
Liang, Ruifang
Huang, Kaiyue
Pfannstiel, Jens
Huang, Min-Chuan https://orcid.org/0000-0002-0704-3447
Lin, Neng-Yu
Ramming, Andreas
Schett, Georg https://orcid.org/0000-0001-8740-9615
Distler, Jörg H. W. https://orcid.org/0000-0001-7408-9333
-
Funding
Funding for this research was provided by:
Friedrich Alexander University of Erlangen Nuremberg | Medizinische Fakultät, Friedrich-Alexander-Universität Erlangen-Nürnberg (A79, A64, J82, 19-12-06-1-Matei, 21-07-23-1-Györfi, J40, A64)
Deutsche Forschungsgemeinschaft (DI 1537/14-1, DI 1537/17-1, DI 1537/20-1, DI 1537/22-1, SFB CRC1181 (project C01), 324392634 (B04), MA 9219/2-1, RA 2506/3-1)
China Scholarship Council
Bundesministerium für Bildung und Forschung (MASCARA program/ TP2 (01EC1903A))
- License Information
-
More Information
Article History
Received: 5 August 2021
Revised: 25 January 2022
Accepted: 28 February 2022
First Online: 26 July 2022
Competing interests
: Although none of the authors has any direct conflict of interest related to O-GlcNAcylation in osteoclasts, J.H.W.D. are involved in the development of new targeted therapies for fibrotic diseases such as SSc. J.H.W.D. has consultancy relationships with Actelion, Active Biotech, Anamar, ARXX, Bayer Pharma, Boehringer Ingelheim, Celgene, Galapagos, GSK, Inventiva, JB Therapeutics, Medac, Pfizer, RuiYi and UCB. J.H.W.D. has received research funding from Anamar, Active Biotech, Array Biopharma, aTyr, BMS, Bayer Pharma, Boehringer Ingelheim, Celgene, Galapagos, GSK, Inventiva, Novartis, Sanofi-Aventis, RedX, UCB. J.H.W.D. is stock owner of 4D Science and Scientific head of FibroCure.
